Gilenya® data confirm reducing brain shrinkage matters for people with MS due to its association with long-term disability progression Novartis, 10 Sep 2014 Accessed on 16 Sep 2014 from http://www.novartis.com/newsroom/media-releases/en/2014/1854831.shtml. CommentRecommendBookmarkWatch